An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression.

Trial Profile

An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Riluzole (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 Results published in the Journal of Clinical Psychopharmacology
    • 22 Apr 2016 Status changed from completed to discontinued.
    • 20 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top